Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass

Area of Science:

• Oncology
• Molecular Biology
• Muscle Physiology

Background:

• Cachexia, a complex wasting syndrome, significantly impacts late-stage cancer patients, particularly those with ovarian cancer.
• Current treatments for cancer-induced muscle atrophy are limited.
• Previous research indicated Withaferin A (WFA) attenuates ovarian cancer cachexia in preclinical models, but its direct effect on skeletal muscle was unclear.

Purpose of the Study:

• To investigate whether Withaferin A (WFA) regulates skeletal muscle mass independently of its anti-tumorigenic effects.
• To determine WFA's impact on muscle function and mass in both tumor-free and tumor-bearing conditions.

Main Methods:

• Preclinical mouse models were utilized.
• Mice were treated with Withaferin A (WFA) under both tumor-free (naïve) and tumor-bearing conditions.
• Muscle mass, functional strength, myogenic progenitors, and proteolytic degradation pathways were assessed.

Main Results:

• Withaferin A (WFA) treatment improved muscle mass and functional strength in both naïve and tumor-bearing mice.
• WFA demonstrated antagonistic effects against ovarian cancer on key skeletal muscle regulatory systems.
• Specifically, WFA modulated myogenic progenitor activity and proteolytic degradation pathways.

Conclusions:

• Withaferin A (WFA) possesses direct hypertrophying effects on skeletal muscle, independent of its anti-tumorigenic properties.
• WFA's ability to target skeletal muscle directly suggests its potential as an effective anti-cachectic agent for ovarian cancer patients.
• This study provides novel insights into WFA's dual role in combating cancer and preserving muscle health.